Abstract
Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels. This may induce rapid bone loss. Tamoxifen is a partial oestrogen receptor agonist and antagonist (classified as a selective oestrogen receptor modulator or SERM). As it has agonistic effects on oestrogen receptors of bone it increases bone mineral density and thus may potentially prevent fractures. In contrast aromatase inhibitors such as anastrozole lead to a decrease in bone mineral density and an increased risk of fractures. Most high-dose intravenous chemotherapeutic regimens induce rapid bone loss from effects on the gonads with induction, for example, of premature menopause. Low-dose oral agents such as methotrexate are not associated with an increased risk of fractures. Androgen deprivation therapies such as LHRH agonists in breast cancer are also associated with an increase in bone loss and an increased risk of fractures. With the increasing long-term survival of patients with cancer, preventive measures against osteoporosis must be considered.
Keywords: Skeletal Effects of Drugs, Cancer, sex steroid levels, Tamoxifen, bone mineral density, aromatase inhibitors, osteoporosis, antagonist
Current Drug Safety
Title: Skeletal Effects of Drugs to Treat Cancer
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Skeletal Effects of Drugs, Cancer, sex steroid levels, Tamoxifen, bone mineral density, aromatase inhibitors, osteoporosis, antagonist
Abstract: Drugs used to treat cancer may affect the skeleton in several ways, the most important being a decrease in sex steroid levels. This may induce rapid bone loss. Tamoxifen is a partial oestrogen receptor agonist and antagonist (classified as a selective oestrogen receptor modulator or SERM). As it has agonistic effects on oestrogen receptors of bone it increases bone mineral density and thus may potentially prevent fractures. In contrast aromatase inhibitors such as anastrozole lead to a decrease in bone mineral density and an increased risk of fractures. Most high-dose intravenous chemotherapeutic regimens induce rapid bone loss from effects on the gonads with induction, for example, of premature menopause. Low-dose oral agents such as methotrexate are not associated with an increased risk of fractures. Androgen deprivation therapies such as LHRH agonists in breast cancer are also associated with an increase in bone loss and an increased risk of fractures. With the increasing long-term survival of patients with cancer, preventive measures against osteoporosis must be considered.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Skeletal Effects of Drugs to Treat Cancer, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699522
DOI https://dx.doi.org/10.2174/157488608785699522 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation
Current Neuropharmacology Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews The Progress of the Anticancer Agents Related to the Microtubules Target
Mini-Reviews in Medicinal Chemistry Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template
Recent Patents on Anti-Cancer Drug Discovery Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Possible Selective Cytotoxicity of Vanadium Complex on Breast Cancer Cells Involving Pathophysiological Pathways
Anti-Cancer Agents in Medicinal Chemistry miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Breast Cancer in Four Continents: Europe, Asia, North and South America. A Report of a Personal Training Experience
Current Women`s Health Reviews Th1-mediated Pathology in Mouse Models of Human Disease is Ameliorated by Concurrent Th2 Responses to Parasite Antigens
Current Topics in Medicinal Chemistry Synthesis, Antiproliferative Activity and Molecular Docking of New Thiazole/Benzothiazole Fused Pyranopyrimidine Derivatives
Letters in Organic Chemistry